Learning Objectives

At the end of this educational activity, participants should be able to:

  • Recognize the latest systemic therapies for renal cell carcinoma
  • Combine immune checkpoint inhibitors and targeted agents
  • Identify and select patients who would benefit from these therapeutic approaches
  • Monitor treatment response and mitigate adverse events

Continue